Researchers have found the strongest evidence yet that the shingles vaccination reduces the risk of developing dementia. A study tracking over 280,000 older adults in Wales found that those who received the Zostavax vaccine were 20% less likely to be diagnosed with dementia over seven years compared to those who didn’t receive it.
The study used a unique approach, comparing dementia rates among two groups of people born weeks apart but on either side of a vaccination eligibility divide. The findings suggest that shingles vaccines may shield against dementia by reducing inflammation in the nervous system or altering the immune system in protective ways.
While the exact mechanism is unclear, the researchers believe that these effects are more pronounced in women. Further research is needed to confirm the benefits and identify the underlying mechanisms. A randomized clinical trial is planned to test the vaccine’s effectiveness in preventing dementia. The study strengthens the link between shingles vaccination and reduced dementia risk, offering new avenues for prevention and treatment.
Source: https://www.theguardian.com/society/2025/apr/02/study-finds-strongest-evidence-yet-that-shingles-vaccine-helps-cut-dementia-risk